The Cu2+ Binding Properties of Branched Peptides Based on l-2,3-Diaminopropionic Acid
摘要:
Three new branched peptides, namely, H-GlyDap(H-Gly)-Gly-NH2 (3G), H-His-Dap(H-His)-Gly-NH2 (2HG), and H-Gly-Dap(H-Gly)-1-Iis-NH2 (2GH), where Dap stands for the 2,3-diaminopropionic acid residue, were synthesized by solid phase procedures. Because of the junction at Dap these peptides have three available pending arms for metal chelation. The complex formation between these peptides and 1 equiv of Cu2+ was investigated as a function of pH by potentiometry ultraviolet-visible absorption, circular dichroism, and X-band electron paramagnetic resonance spectroscopy in aqueous medium. Our results clearly demonstrate that cooperation between all three peptide arms essentially contributes to the stability of copper(II) complexes.
[EN] INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH<br/>[FR] ANALOGUES DE L'INSULINE À COMMUTATEUR DE CONFORMATION RÉGULÉ PAR LE GLUCOSE
申请人:THERMALIN INC
公开号:WO2021022116A1
公开(公告)日:2021-02-04
The present invention relates to glucose-responsive insulin analogues, compositions including the glucose-responsive insulin analogues, and methods of lowering blood sugar of a patient using the insulin analogue or compositions thereof.
[EN] GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES<br/>[FR] DÉRIVÉS DE LIAISON À L'ALBUMINE SENSIBLES AU GLUCOSE
申请人:NOVO NORDISK AS
公开号:WO2019092125A1
公开(公告)日:2019-05-16
This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X-R2, and wherein "X" is a mono- to multiatomic linker and where R1 and R2, which may be identical or different, each represents a group of Formula (lla) or (IIb) Also described are diboron conjugates represented by the general Formula (I'), which is: R1'-X'-R2', in which either the moeities R1' or R2' or X' carry a drug that is covalently attached to the diboron compound.
[EN] METHODS OF TREATING CANCER WITH A PSMA LIGAND-TUBULYSIN COMPOUND<br/>[FR] MÉTHODES DE TRAITEMENT DU CANCER AVEC UN COMPOSÉ LIGAND DE PSMA-TUBULYSINE
申请人:ENDOCYTE INC
公开号:WO2017205447A1
公开(公告)日:2017-11-30
The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating PSMA expressing cancers with a PSMA ligand-tubulysin compound. The invention described herein also relates to methods of treating PSMA-expressing cancers with a PSMA ligand-tubulysin compound in patients where stable disease results after treatment with the PSMA ligand-tubulysin compound.
A molecule is disclosed having the following structure:
wherein
T is D or A
D being a residue of an amine containing biologically active molecule and
A being a leaving group.
揭示了具有以下结构的分子:其中T为D或AD,是含有生物活性分子的胺基残基,A为离去基团。
Artificial aldolases from peptide dendrimer combinatorial libraries
作者:Jacob Kofoed、Tamis Darbre、Jean-Louis Reymond
DOI:10.1039/b607342e
日期:——
Peptidedendrimers were investigated as synthetic models for aldolase enzymes. Combinatorial libraries were prepared with aldolase active residues such as lysine and proline placed at the dendrimer core or near the surface. On-bead selection for aldolase activity was carried out using the dye-labelled 1,3-diketone 1a, suitable for covalent trapping of enamine-reactive side-chains, and the fluorogenic